Fri, April 5th 2024 at 4:39 AM
The drug’s failure is a major disappointment for ALS patients and advocates who pressed the FDA to approve it in September 2022. That approval was based, in part, on results from one small mid-stage study that was actually criticized by some of the FDA's own scientists.Doctor Vincent LaBarbera, the medical director of the Louise Wilcox ALS clinic in Rhode Island, wrote, in part, in a statement:
"For those of you who are currently receiving the medication, it will be a discussion of pros/cons with your neurologist as to whether or not to continue the medication.
Now that Relyvrio is off the market, there are three FDA approved drugs for ALS. But because this disease is progressive and fatal, at best medications usually extend life a few months.
Source: Entertainment Trends (entertainmenttrends.net)
INC. The Als Association Amylyx Pharmaceuticals Health_Medical_Pharma Rhode Island United States Christina Vilardi Vincent Labarbera Als Sodium Phenylbutyrate/Ursodoxicoltaurine THE AMYOTROPHIC LATERAL SCLEROSIS ASSOCIATION Orphan Drugs Food And Drug Administration Approved Drug
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
Source: AP - 🏆 728. / 51 Read more »
Amylyx Ditches Controversial ALS Drug RelyvrioAfter disappointing phase 3 trial results in ALS, Amylyx will pull Relyvrio from the market but provide it free to patients who want to stay on the medication.
Source: Medscape - 🏆 386. / 55 Read more »
Amylyx Pharmaceuticals to Remove ALS Drug from MarketAmylyx Pharmaceuticals has announced that it will voluntarily remove its drug for amyotrophic lateral sclerosis (ALS) from the market. This decision comes after a recent clinical trial showed that the treatment is ineffective.
Source: washingtonpost - 🏆 95. / 72 Read more »
Amylyx Pharmaceuticals to Pull Drug for Lou Gehrig’s Disease from MarketAmylyx said last month it was considering pulling its drug Relyvrio after a clinical trial in 600 patients failed to show any improvements in survival or other health measures. The maker of the drug has now announced that it will voluntarily halt sales and marketing of the drug, acknowledging its lack of effectiveness in helping patients with the deadly neurological condition.
Source: nbcsandiego - 🏆 524. / 51 Read more »
ALS drug Relyvrio withdrawn from market after failed clinical trialThe pharmaceutical company that produced the drug said it would continue to evaluate and share findings from the clinical trial to help inform future ALS research.
Source: WGAL - 🏆 331. / 59 Read more »
Amylyx May Pull FDA-Approved ALS Drug After Failed Phase 3 TrialTopline results for the ALS drug Relyvrio show that it failed to meet primary or secondary endpoints. The company says it may voluntarily pull the drug from the market.
Source: Medscape - 🏆 386. / 55 Read more »